Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 10170A100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Zachary Hornby 13G | 9.8% |
8/27/2026
Event 10/14/2025
|
|
|
ADAR1 Capital Management, LLC
13G
|
8.8% |
8/14/2026
Event 6/30/2026
|
|
| ADAR1 Capital Management, LLC | 8.8% | ||
| Daniel Schneeberger | 8.8% | ||
|
Citadel Advisors LLC
13G/A
Amendment 1
|
0.6% |
8/14/2026
Event 6/30/2026
|
|
| Citadel Advisors LLC | 0% | ||
| Citadel Advisors Holdings LP | 0% | ||
| Citadel GP LLC | 0% | ||
| Citadel Securities LLC | 0.3% | ||
| Citadel Securities Group LP | 0.6% | ||
| Citadel Securities GP LLC | 0.6% | ||
| Kenneth Griffin | 0.6% | ||
|
Tang Capital Management LLC
13G
|
11.3% |
6/29/2026
Event 6/23/2026
|
|
| Tang Capital Management, LLC | 11.3% | ||
| Kevin Tang | 11.3% | ||
| Tang Capital Partners, LP | 2.6% | ||
| Tang Capital Partners International, LP | 3.5% | ||
| Tang Capital Partners III, Inc | 2.6% | ||
| Tang Capital Partners IV, Inc | 2.6% | ||
|
Nextech VI GP S.A.R.L.
13G/A
Amendment 1
|
0% |
2/17/2026
Event 12/31/2025
|
|
| Nextech VI GP S.a. r.l. | 0% | ||
| Nextech VI Oncology SCSp | 0% | ||
| Ian Charoub | 0% | ||
| Costas Constantinides | 0% | ||
| Rocco Sgobbo | 0% | ||
|
FMR LLC
13G/A
Amendment 1
|
12.0% |
2/5/2026
Event 12/31/2025
|
|
| FMR LLC | 12.0% | ||
| Abigail P. Johnson | 12.0% | ||
|
Citadel Advisors LLC
13G
|
6.4% |
12/4/2025
Event 11/26/2025
|
|
| Citadel Advisors LLC | 3.7% | ||
| Citadel Advisors Holdings LP | 3.7% | ||
| Citadel GP LLC | 3.7% | ||
| Citadel Securities LLC | 2.7% | ||
| Citadel Securities Group LP | 2.7% | ||
| Citadel Securities GP LLC | 2.7% | ||
| Kenneth Griffin | 6.4% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 1
|
0% |
8/14/2025
Event 6/30/2025
|
|
| RA Capital Management, L.P. | 0% | ||
| Peter Kolchinsky | 0% | ||
| Rajeev Shah | 0% | ||
| RA Capital Healthcare Fund, L.P. | 0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 40 | 15.3 M | $38.3 M |
| 2026 Q1 | 36 | 8.49 M | $9.33 M |
| 2025 Q4 | 37 | 8.98 M | $10.8 M |
| 2025 Q3 | 36 | 9.71 M | $11.9 M |
| 2025 Q2 | 46 | 9.79 M | $9.88 M |
| 2025 Q1 | 55 | 17.0 M | $419 M |
| 2024 Q4 | 56 | 13.0 M | $37.6 M |
| 2024 Q3 | 57 | 13.3 M | $46.1 M |
| 2024 Q2 | 50 | 14.0 M | $54.2 M |
| 2024 Q1 | 44 | 14.6 M | $209 M |